HWHG(SH:600079) Xin Lang Cai Jing·2025-12-17 02:29Core Viewpoint - The China Securities Regulatory Commission (CSRC) has issued a preliminary administrative penalty notice against Renfu Pharmaceutical Group Co., Ltd. for violations related to information disclosure, leading to potential legal actions from affected investors [1][6]. Summary by Sections Regulatory Actions - The CSRC's Hubei Regulatory Bureau has completed its investigation into Renfu Pharmaceutical and is set to impose administrative penalties due to violations of the Securities Law of the People's Republic of China [1][6]. Violations Identified - Key violations include failure to timely disclose significant litigation and arbitration matters, and inaccuracies in goodwill impairment testing for certain subsidiaries, resulting in misleading financial data in annual reports [6][7]. Investor Compensation - Affected investors who purchased Renfu Pharmaceutical stock between April 27, 2021, and October 22, 2024, and held or sold at a loss on October 22, 2024, may be eligible for compensation [2][7]. - Required documentation for claims includes original stock transaction statements, copies of the investor's ID, and a securities account confirmation from the brokerage [3][4][8].